Navigation Links
INNOPHARMA Receives FDA Approval of Generic Levetiracetam Injection

PISCATAWAY, N.J., Aug. 8, 2011 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of its Abbreviated New Drug Application (ANDA) for levetiracetam injection (the generic equivalent of Keppra® injection from UCB Inc).

As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with X-GEN Pharmaceuticals, Inc. for marketing and product distribution in the US.


INNOPHARMA is a sterile product development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at    

About X-GEN:

X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN's expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. For more information about X-GEN Pharmaceuticals, Inc.  call (866) 390-4411, or visit the web-site at

Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. INNOPHARMA Receives First FDA Approval
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.
4. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
5. Ontario Institute for Cancer Research Receives $420 Million Over Five Years for Important Cancer Research in Ontario
6. Good Samaritan Hospitals Wound and Hyperbaric Institute Receives Accreditation from Undersea and Hyperbaric Medical Society, Recognizing Advanced Care
7. Once-Daily Welchol® (colesevelam HCl) for Oral Suspension Receives FDA Approval To be Mixed With Fruit Juice or Diet Soft Drinks
8. Nephros Receives 510k Approval to Market Additional Ultrafiltration Products
9. BioMedix™ Receives Patent for Its Innovative Collaborative Care Business Method
10. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
11. Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... Developmental, commercial, and regulatory/legal strategies ... of pharmaceutical products, says GBI Research ... strategies all play a key role in boosting the ... . --> Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... seniors, is resulting in a way for homeless people to have a more ... launched a new initiative whereby they are repurposing plastic bags into sleeping mats ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Many people ... fatigue, fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find ... diet and exercise regimen instead of their thyroid, especially if they don’t have any ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit ... as well as raising public awareness of the disorder while helping to bring ... donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at ...
(Date:11/25/2015)... ... 25, 2015 , ... Since its launch in 2012, the ... stem cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. ... Trademark (RTM). , Organizations are required to hold a registered trademark in order ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):